Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > ARCHIVE
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
- The Art of Business
September 26, 2011
- Actos Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
August 29, 2011
- Korosho to Grant Subsidies to 4 Companies to Develop, Manufacture New Flu Vaccines
August 29, 2011
- Use Medicoeconomic Evaluation in NHI Drug Pricing: Korosho Study Group
August 29, 2011
- Novartis Pharma to Ask Korosho Why It Was Not Selected for Vaccine Grant
August 29, 2011
- Korosho Orders Revision of Package Insert, “Blue Letter”for Prazaxa after 5 Deaths
August 29, 2011
- NanoCarrier Ties Up with Kyoto Univ. for Nucleic Acid Drugs
August 29, 2011
- AZ Aims to Make Nexium the No. 1 PPI in Japan
August 29, 2011
- Celsentri Approved for Naive HIV-Infected Patients: ViiV Healthcare
August 29, 2011
- AnGes MG to Jointly Develop Therapeutic HPV Vaccine with GenoLac
August 29, 2011
- NBI Increasing Efforts to Ensure Proper Use of Prazaxa
August 29, 2011
- Remicade Obtains Approval for Partial Changes in Dosage for Crohn's Disease
August 29, 2011
- Mitsubishi Chemical Medience Begins Contract Synthesis of Radiolabeled Compounds
August 29, 2011
- Emerging Markets, Japan Drove Growth in 1st Half of 2011 for Global Megapharmas
August 29, 2011
- Hisamitsu to Apply for Transdermal Oxybutynin for OAB in FY2012
August 29, 2011
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…